New therapies for the treatment of congestive heart failure

Drugs of Today

Volumn 38, Issue 1, 2002, Pages 31-48

  Burger, Andrew J ^a   Burger, Mary R ^a   Aronson, Doron ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM SENSITIZER; CANDOXATRIL; CANRENOIC ACID; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; CYTOKINE ANTIBODY; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; ENOXIMONE; ENRASENTAN; EPLERENONE; ETANERCEPT; GLYCERYL TRINITRATE; INFLIXIMAB; LEVOSIMENDAN; NESIRITIDE; OMAPATRILAT; PIMOBENDAN; RAMIPRIL; SPIRONOLACTONE; TEZOSENTAN; VASOPEPTIDASE INHIBITOR; VASOPRESSIN ANTAGONIST; ALDOSTERONE RECEPTOR; CYTOKINE; ENDOTHELIN RECEPTOR; NATRIURETIC FACTOR; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; VASOPRESSIN DERIVATIVE;

ABDOMINAL PAIN; BLOOD VOLUME; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; NAUSEA; REVIEW; TREATMENT INDICATION; VERTIGO; ANIMAL; CALCIUM SIGNALING; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY;

ANIMAL; CALCIUM SIGNALING; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMAN; NATRIURETIC HORMONE; PHOSPHODIESTERASE INHIBITORS; PROTEASE INHIBITORS; RECEPTORS, ALDOSTERONE; RECEPTORS, ENDOTHELIN; VASOPRESSINS; ANIMALS; HUMANS; NATRIURETIC AGENTS;

EID: 0036120008     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.1.660506     Document Type: Review

References (118)

1. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary
2. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)
3. Guidelines for the diagnosis and treatment of chronic heart failure
4. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
5. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
7. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
8. Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement
9. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
10. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
11. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
12. Clinical trials update: Highlights of the scientific sessions of the American Heart Association year 2000: Val HEFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
13. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
14. The effect of digoxin on mortality and morbidity in patients with heart failure
15. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: The DIG study
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
18. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
19. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
20. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
21. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
22. Effect of carvedilol on survival in severe chronic heart failure
23. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
24. Inotropic therapy for heart failure
25. Parenteral inotropic support for advanced congestive heart failure
26. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
27. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction
28. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
29. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
30. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
31. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure
32. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
33. Therapeutic potential of nesiritide (recombinant B-type natriuretic peptide) in the treatment of heart failure
34. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
35. Repetitive bolus administration of brain natriuretic peptide reduces cardiac filling pressures in human heart failure
36. Natriuretic peptides in the treatment of heart failure
37. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial
38. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
39. Recombinant human B-type natriuretic peptide improves symptoms and hemodynamics in patients with acutely decompensated CHF
40. Nesiritide improves hemodynamics in patients with acutely decompensated heart failure
41. Nesiritide (human B-type natriuretic peptide) improves symptoms and hemodynamics in NYHA Class III and IV heart failure
42. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
43. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy
44. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure
45. The effect of short term therapy with nesiritide (B-type natriuretic peptide) or dobutamine on long term survival
46. Effect of nesiritide, B-type natriuretic peptide, on endothelin-1 in patients with decompensated congestive heart failure
47. Results of the VMAC trial: Vasodilation in the management of acute congestive heart failure
48. Plasma endothelin in chronic heart failure
49. Endothelin in human congestive heart failure
50. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
51. Endothelins
52. Cloning and expression of a cDNA encoding an endothelin receptor
53. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
54. Cellular signaling by peptides of the endothelin gene family
55. Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Crosstalk between G protein-coupled receptors and pp60c-src
56. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
57. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells
58. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
59. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
60. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats
61. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
62. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload
63. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy
64. Integrated cardiac, renal, and endocrine actions of endothelin
65. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs
66. Electrophysiological effects of intrapericardial infusion of endothelin-1
67. Evidence for direct arrhythmogenic action of endothelin
68. Electrophysiological effects of endothelin-1 on canine myocardial cells
69. Investigating the dual nature of endothelin-1: Ischemia or direct arrhythmogenic effect?
70. Intrapericardial infusion of endothelin-1 induces ventricular arrhythmias in dogs
71. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?
72. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
73. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
74. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
75. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
76. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure (RITZ 1)
77. A prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of tezosentan in patients with acute decompensated heart failure (RITZ 2)
78. A multicenter randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of tezosentan in patients with acute decompensated heart failure and acute coronary syndrome (RITZ 4)
79. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
80. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
81. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
82. Pharmacology of bipyridine phosphodiesterase III inhibitors
83. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
84. Effect of oral milrinone on mortality in severe chronic heart failure
85. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo
86. Low-dose enoximone improves exercise capacity in chronic heart failure
87. Outcomes of a prospective trial of intravenous (IV) milrinone for exacerbations of chronic heart failure (OPTIME-CHF)
88. Heart failure etiology and response to intravenous milrinone in decompensated heart failure: The OPTIME-CHF study
89. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure
90. Will calcium sensitizers play a role in the treatment of heart failure?
91. Calcium sensitizers in chronic heart failure: Inotropic interventions-reservation to preservation
92. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure
93. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure
94. Efficacy and safety of intravenous levosimendan in severe low-output heart failure
95. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
96. The effects of long-term treatment with pimobendan on mortality and morbidity in patients with moderate chronic heart failure (a placebo-controlled, randomized, double-blind long-term study-EPOCH Study)
97. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure
98. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure
99. Vasopeptidase inhibition: A new concept in blood pressure management
100. Effects of omapatrilat on hemodynamics and safety in patients with heart failure
101. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
102. Vasopeptidase inhibition and angio-oedema
103. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists
104. Vasopressin V2 receptor antagonists
105. Urinary water clearance after infusion of conivaptan, a combined vasopressin Vla and V2 receptor antagonist, in patients with NYHA class III/IV heart failure
106. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure - A randomized double-blind trial
107. Vasopressin V2 receptor blockade versus fluid restriction in the treatment of hyponatremia: Results from a multicenter randomized controlled trial
108. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
109. Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study
110. Eplerenone: A selective aldosterone receptor antagonist (SARA)
111. Exciting new drugs on the horizon - Eplerenone, a selective aldosterone receptor antagonist (SARA)
112. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
113. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
114. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
115. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
116. Cytokines and cardiac contractile function
117. The role of cytokines in the failing human heart
118. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure